摘要
目的探讨CD10、CD30、CD138、Bcl-6及Mum-1/IRF-4与弥漫性大B细胞性淋巴瘤(DLBCL)的分子亚型及预后的关系。方法对73例DLBCL进行HE及免疫组化染色、光镜观察,随访所有患者并分析临床资料。结果单因素分析,Bcl-6和Mum-1的表达是影响生存的重要因素,P值分别为0.028和0.001。CD138阳性可能提示患者预后不良。按Hans分组标准将患者分为两组,GCB型19例(26%);non-GCB型54例(74%),两型预后差异无统计学意义。按Chang标准分为4组:A组5例(6.9%);B组29例(39.7%);C组29例(39.7%);D组10例(13.7%)。其中B组患者预后相对较好,D组患者最差,C组预后介于两组之间。结论DLBCL中,Bcl-6、Mum-1阳性患者预后好;CD138的表达可能提示预后不良。
Objective To evaluate if using a panel of markers such as CD10, CD30, CD138, Bcl-6 and Mum1/IRF4 by immunohistochemistry defines prognosis in patients with diffuse large B-cell lymphoma （DLBCL）. Methods Immunohistochemical stains for the above markers were performed on paraffin-embedded tissues of 73 patients consecutively diagnosed with DLBCL. Results The univariate analysis demonstrated that the expression of Bcl-6 and Mum-1 were significant prognosis factors, with P values of 0. 028 and 0. 001. CD138 （P=0.210） may play an important role as a poor prognostic marker. Moreover, when the patients were subdivided according to Hans, there is no difference between GCB（19 patients, 26%） and non-GCB（54 patients, 74%） in survival rate （P=0.959）. Using the four groups classification of Chang,5 patients （6. 9%） were subclassified as pattern A,29 （39. 7%） as B and C separately,and 10 （13.7%） as D. Among the four patterns, pattern B showed a better survival rate, pattern D had a signifi cantly lower survival rate,and pattern C is between the two groups. Conclusion In the present study,the expression of Bcl-6 and Mum-1 were associated with particular clinicopathologic features and outcome, which were favourable prognostic factors. CD138 may play an important role as a poor prognostic marker.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2008年第11期796-799,共4页
Cancer Research on Prevention and Treatment
关键词
弥漫性大B细胞性淋巴瘤
分子表型
免疫组织化学
预后
Diffuse Large B-cell lymphoma
molecular classification
Immunohistochemistry
prognosis factors
